Cargando…

15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury

The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PG...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byeong Woo, Kim, Hye Jung, Kim, Sun-Hee, Baik, Hyung Joo, Kang, Mi Seon, Kim, Dong-Hyun, Markowitz, Sanford D., Kang, Sun Woo, Bae, Ki Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832987/
https://www.ncbi.nlm.nih.gov/pubmed/33459127
http://dx.doi.org/10.1080/0886022X.2020.1870139
_version_ 1783641961841819648
author Kim, Byeong Woo
Kim, Hye Jung
Kim, Sun-Hee
Baik, Hyung Joo
Kang, Mi Seon
Kim, Dong-Hyun
Markowitz, Sanford D.
Kang, Sun Woo
Bae, Ki Beom
author_facet Kim, Byeong Woo
Kim, Hye Jung
Kim, Sun-Hee
Baik, Hyung Joo
Kang, Mi Seon
Kim, Dong-Hyun
Markowitz, Sanford D.
Kang, Sun Woo
Bae, Ki Beom
author_sort Kim, Byeong Woo
collection PubMed
description The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which degrades prostaglandin E(2) (PGE2), promotes tissue repair and regeneration in many organs. PGE2 causes intrarenal arterial vasodilation. In this study, we investigated whether a 15-PGDH inhibitor can act as a candidate for blocking these two major mechanisms of CIAKI. We established a CIAKI mouse model by injecting a 10 gram of iodine per body weight (gI/kg) dose of iodixanol into each mouse tail vein. A 15-PGDH inhibitor (SW033291), PGE1, or PGE2 were administered to compare the renal functional parameters, histologic injury, vasoconstriction, and renal blood flow changes. In addition, human renal proximal tubular epithelial cells were cultured in a CM-treated medium. SW033291, PGE1, or PGE2 were added to compare any changes in cell viability and apoptosis rate. CIAKI mice that received SW033291 had lower serum levels of creatinine, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1 (p < 0.001); lower histologic injury score and TUNEL positive rates (p < 0.001); and higher medullary arteriolar area (p < 0.05) and renal blood flow (p < 0.001) than CM + vehicle group. In cell culture experiments, Adding SW033291 increased the viability rate (p < 0.05) and decreased the apoptosis rate of the tubular epithelial cells (p < 0.001). This 15-PGDH inhibitor blocks the two primary mechanisms of CIAKI, intrarenal vasoconstriction and tubular cell toxicity, and thus has the potential to be a novel prophylaxis for CIAKI. Abbreviations: 15-PGDH: 15-hydroxyprostaglandin dehydrogenase; AMP: adenosine monophosphate; CIAKI: contrast-induced acute kidney injury; CM: contrast media; EP: prostaglandin E2 receptor; hRPTECs: human-derived renal proximal tubule epithelial cells; KIM-1: kidney injury molecule-1; MTT: 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NGAL: neutrophil gelatinase-associated lipocalin; PBS: phosphate-buffered saline; PGE1: prostaglandin E(1); PGE2: prostaglandin E(2); RBF: renal blood flow; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; α-SMA: α-Smooth muscle actin
format Online
Article
Text
id pubmed-7832987
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-78329872021-02-02 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury Kim, Byeong Woo Kim, Hye Jung Kim, Sun-Hee Baik, Hyung Joo Kang, Mi Seon Kim, Dong-Hyun Markowitz, Sanford D. Kang, Sun Woo Bae, Ki Beom Ren Fail Laboratory Study The two primary mechanisms by which iodinated contrast media (CM) causes contrast-induced acute kidney injury (CIAKI) are the hemodynamic effect causing intrarenal vasoconstriction and the tubular toxic effect causing acute tubular necrosis. Inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which degrades prostaglandin E(2) (PGE2), promotes tissue repair and regeneration in many organs. PGE2 causes intrarenal arterial vasodilation. In this study, we investigated whether a 15-PGDH inhibitor can act as a candidate for blocking these two major mechanisms of CIAKI. We established a CIAKI mouse model by injecting a 10 gram of iodine per body weight (gI/kg) dose of iodixanol into each mouse tail vein. A 15-PGDH inhibitor (SW033291), PGE1, or PGE2 were administered to compare the renal functional parameters, histologic injury, vasoconstriction, and renal blood flow changes. In addition, human renal proximal tubular epithelial cells were cultured in a CM-treated medium. SW033291, PGE1, or PGE2 were added to compare any changes in cell viability and apoptosis rate. CIAKI mice that received SW033291 had lower serum levels of creatinine, neutrophil gelatinase-associated lipocalin, and kidney injury molecule 1 (p < 0.001); lower histologic injury score and TUNEL positive rates (p < 0.001); and higher medullary arteriolar area (p < 0.05) and renal blood flow (p < 0.001) than CM + vehicle group. In cell culture experiments, Adding SW033291 increased the viability rate (p < 0.05) and decreased the apoptosis rate of the tubular epithelial cells (p < 0.001). This 15-PGDH inhibitor blocks the two primary mechanisms of CIAKI, intrarenal vasoconstriction and tubular cell toxicity, and thus has the potential to be a novel prophylaxis for CIAKI. Abbreviations: 15-PGDH: 15-hydroxyprostaglandin dehydrogenase; AMP: adenosine monophosphate; CIAKI: contrast-induced acute kidney injury; CM: contrast media; EP: prostaglandin E2 receptor; hRPTECs: human-derived renal proximal tubule epithelial cells; KIM-1: kidney injury molecule-1; MTT: 3-(4,5-Dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NGAL: neutrophil gelatinase-associated lipocalin; PBS: phosphate-buffered saline; PGE1: prostaglandin E(1); PGE2: prostaglandin E(2); RBF: renal blood flow; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling; α-SMA: α-Smooth muscle actin Taylor & Francis 2021-01-17 /pmc/articles/PMC7832987/ /pubmed/33459127 http://dx.doi.org/10.1080/0886022X.2020.1870139 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Laboratory Study
Kim, Byeong Woo
Kim, Hye Jung
Kim, Sun-Hee
Baik, Hyung Joo
Kang, Mi Seon
Kim, Dong-Hyun
Markowitz, Sanford D.
Kang, Sun Woo
Bae, Ki Beom
15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title_full 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title_fullStr 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title_full_unstemmed 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title_short 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
title_sort 15-hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury
topic Laboratory Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832987/
https://www.ncbi.nlm.nih.gov/pubmed/33459127
http://dx.doi.org/10.1080/0886022X.2020.1870139
work_keys_str_mv AT kimbyeongwoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT kimhyejung 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT kimsunhee 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT baikhyungjoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT kangmiseon 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT kimdonghyun 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT markowitzsanfordd 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT kangsunwoo 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury
AT baekibeom 15hydroxyprostaglandindehydrogenaseinhibitorpreventscontrastinducedacutekidneyinjury